UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Amyloidosis Diagnosed in Solid Organ Transplant Recipients

Sharpley, FA; Fontana, M; Gilbertson, JA; Gillmore, JD; Hawkins, PN; Mahmood, S; Manwani, R; ... Lachmann, HJ; + view all (2020) Amyloidosis Diagnosed in Solid Organ Transplant Recipients. Transplantation , 104 (2) pp. 415-420. 10.1097/TP.0000000000002813. Green open access

[thumbnail of Gillmore_Transplantation manuscript clean version 17.05.19.pdf]
Preview
Text
Gillmore_Transplantation manuscript clean version 17.05.19.pdf - Accepted Version

Download (372kB) | Preview

Abstract

Background: Development of amyloidosis post solid-organ transplantation has not been reported, although plasma cell neoplasms are a rare form of posttransplant lymphoproliferative disorder, which could be complicated by light chain amyloidosis (AL) amyloidosis. / Methods: We searched our database of 5112 patients seen between 1994 and 2018 with a diagnosis of amyloidosis post solid-organ transplant. Patients were excluded if the amyloid diagnosis preceded the transplant date. The indication and type of organ transplant were recorded in addition to the amyloidosis type, organs involved, treatment given, and survival. / Results: Thirty patients were identified. The median age at diagnosis with amyloidosis was 52 years (range 33–77). The median time from transplantation to diagnosis was 10.5 years (0.58–36). The grafts were kidney (N = 25, 83.3%), liver (N = 2, 6.7%), heart (N = 2, 6.7%), and combined heart, lung, and kidney (N = 1, 3.3%). The type of amyloidosis was systemic AL (N = 14, 47%), serum amyloid A amyloidosis (AA) (N = 11, 37%), localized AL (N = 3, 10%), wild-type transthyretin amyloidosis (ATTR) (N = 1, 3.3%), and amyloid of uncertain type (N = 1, 3.3%). Renal graft dysfunction was seen in 11 of 25 (44%) cases. Median graft survival was 185 months (96–269), and median survival from diagnosis with amyloidosis was 45 months (2–89); median survival by amyloidosis type was localized AL: 64 months (20–67), systemic AL: 23.5 months (0–95), ATTR amyloidosis: 17 months, and AA, 15 months (0–77). / Conclusions: This series is the first description of amyloidosis post solid-organ transplant; 30 cases among 5112 amyloid patients >24 years suggests that amyloidosis may occur post solid-organ transplantation with an overall poor survival.

Type: Article
Title: Amyloidosis Diagnosed in Solid Organ Transplant Recipients
Open access status: An open access version is available from UCL Discovery
DOI: 10.1097/TP.0000000000002813
Publisher version: https://doi.org/10.1097/TP.0000000000002813
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10099128
Downloads since deposit
164Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item